Brand-name drug
Climara price, strengths & recalls
Brand of estradiol (generic)
Pharmacies pay $510.47 for 28 ds of Climara 0.00104 mg/hr (168 hr) patch this week, and from $508.85 to $512.26 across its 6 priced strengths and forms. The generic, estradiol, costs pharmacies from $1.86. It has 253 recalls on record, none ongoing. Its official label last changed on March 30, 2026.
Brand- Fair cash price
- $597.54
- Strengths
- 6
- Makers
- 1
- Updated
- Nov 11
Climara price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for the usual package. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 0.00104 mg/hr (168 hr) patch Brand | $18.23 | $510.47 / 28 ds |
| 0.00156 mg/hr (168 hr) patch Brand | $18.30 | $512.26 / 28 ds |
| 0.00208 mg/hr (168 hr) patch Brand | $18.26 | $511.39 / 28 ds |
| 0.0025 mg/hr (168 hr) patch Brand | $18.17 | $508.85 / 28 ds |
| 0.00312 mg/hr (168 hr) patch Brand | $18.23 | $510.40 / 28 ds |
| 0.00417 mg/hr (168 hr) patch Brand | $18.26 | $511.33 / 28 ds |
Climara vs generic estradiol
Generics have the same active ingredient, strength and form, and FDA requires them to work the same way. What pharmacies pay for each, same quantity:
| Strength | Brand | Generic | Brand costs |
|---|---|---|---|
| 0.00104 mg/hr (168 hr) patch | $510.47 | $345.29 | 1.5x |
| 0.00156 mg/hr (168 hr) patch | $512.26 | $357.96 | 1.4x |
| 0.00208 mg/hr (168 hr) patch | $511.39 | $342.12 | 1.5x |
| 0.0025 mg/hr (168 hr) patch | $508.85 | $343.59 | 1.5x |
| 0.00312 mg/hr (168 hr) patch | $510.40 | $372.93 | 1.4x |
| 0.00417 mg/hr (168 hr) patch | $511.33 | $357.69 | 1.4x |
Supply status: shortages & recalls
Recalls
Showing the 6 most relevant of 253 - all recalls.
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Climara
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use CLIMARA safely and effectively. See full prescribing information for CLIMARA. Climara® (estradiol transdermal system) Initial U.S. Approval: 1975
WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, PROBABLE DEMENTIA and BREAST CANCER
Estrogen-Alone Therapy
Endometrial Cancer
There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestogen to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Perform adequate diagnostic measures, including directed or random endometrial sampling when indicated to rule out malignancy in postmenopausal women with undiagnosed, persistent or recurring abnormal genital bleeding [see Warnings and Precautions (5.2)].
Cardiovascular Disorders and Probable Dementia
The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg]-alone, relative to placebo [see Warnings and Precautions (5.1), and Clinical Studies (14.3)].
The WHI Memory Study (WHIMS) estrogen-alone ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age and older during 5.2 years of treatment with daily CE (0.625 mg)-alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women [see Warnings and Precautions (5.3), Use in Specific Populations (8.5), and Clinical Studies (14.4)].
Do not use estrogen-alone therapy for the prevention of cardiovascular disease or dementia [see Warnings and Precautions (5.1, 5.3), and Clinical Studies (14.3, 14.4)].
Only daily oral 0.625 mg CE was studied in the estrogen-alone substudy of the WHI. Therefore, the relevance of the WHI findings regarding adverse cardiovascular events and dementia to lower CE doses, other routes of administration, or other estrogen-alone products is not known. Without such data, it is not possible to definitively exclude these risks or determine the extent of these risks for other products. Discuss with your patient the benefits and risks of estrogen-alone therapy, taking into account her individual risk profile.
Prescribe estrogens with or without progestogens at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.
Estrogen Plus Progestin Therapy
Cardiovascular Disorders and Probable Dementia
The WHI estrogen plus progestin substudy reported increased risks of DVT, pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral CE (0.625 mg) combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo [see Warnings and Precautions (5.1), and Clinical Studies (14.3)].
The WHIMS estrogen plus progestin ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age and older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women [see Warnings and Precautions (5.3), Use in Specific Populations (8.5), and Clinical Studies (14.4)].
Do not use estrogen plus progestogen therapy for the prevention of cardiovascular disease or dementia [see Warnings and Precautions (5.1, 5.3), and Clinical Studies (14.3, 14.4)].
Breast Cancer
The WHI estrogen plus progestin substudy also demonstrated an increased risk of invasive breast cancer [see Warnings and Precautions (5.2), and Clinical Studies (14.3)].
Only daily oral 0.625 mg CE and 2.5 mg MPA were studied in the estrogen plus progestin substudy of the WHI. Therefore, the relevance of the WHI findings regarding adverse cardiovascular events, dementia and breast cancer to lower CE plus other MPA doses, other routes of administration, or other estrogen plus progestogen products is not known. Without such data, it is not possible to definitively exclude these risks or determine the extent of these risks for other products. Discuss with your patient the benefits and risks of estrogen plus progestogen therapy, taking into account her individual risk profile.
Prescribe estrogens with or without progestogens at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.
WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, PROBABLE DEMENTIA, and BREAST CANCER,
See full prescribing information for complete boxed warning.
Estrogen-Alone Therapy
There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens (5.2)
The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) (5.1)
The WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older (5.3)
Do not use estrogen-alone therapy for the prevention of cardiovascular disease or dementia (5.1, 5.3)
Estrogen Plus Progestin Therapy
The WHI estrogen plus progestin substudy reported increased risks of stroke, DVT, pulmonary embolism (PE), and myocardial infarction (MI) (5.1)
The WHI estrogen plus progestin substudy reported increased risks of invasive breast cancer (5.2)
The WHIMS estrogen plus progestin ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older (5.3)
Do not use estrogen plus progestogen therapy for the prevention of cardiovascular disease or dementia (5.1, 5.3)
Recent major changes (as listed on the label)
Warnings and Precautions (5.2) | 12/2023 |
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA020375 · Bayer Hlthcare
- First approved
- December 22, 1994 (32 years ago)
- Latest approved change
- February 15, 2024
- Approved label
- PDF, Feb 16, 2024
- Generic makers
- 31 approved generic applications on the market
Climara questions
How much does climara cost without insurance?
Pharmacies pay about $510.47 for 28 ds of climara 0.00104 mg/hr (168 hr) patch ($18.23 per unit). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $597.54. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is there a generic for Climara?
Yes: estradiol. Pharmacies pay from $1.86 for it. Compare estradiol prices.
Is climara in shortage?
No shortage is reported for climara right now. We check the national shortage list every day.
Has climara been recalled?
253 recalls on record, none ongoing. Recalls name specific lots - check yours.
When did the climara label last change?
The official label was last updated on March 30, 2026 (version 25). See what changed.
Talk about climara
No comments yet. Questions, tips, what worked for you - start the conversation.